Intraday Info: AC Immune Ltd (NASDAQ:ACIU) locked on 02/02/2017 at $12.09. It has average volume 63,975 whilst it totals volume 42,456. The company has EPS -0.13. Profit Margin of ACIU -31.30% and it total income -6.90 million.
Ownership Summary: AC Immune Ltd has total institutional ownership 14.48% while its total outstanding shares 55 millions that’s value of holdings $96 million.
Active Positions: In the latest year, ACIU 33 holders have raised its positions while it contains total 8,018,959 shares.
New and Sold Out Positions: In ACIU force of new positions holders 33 and it has total shares 8,018,959.
Comparison with Other Company: The Market Value of ACIU is $652,147 above from AbbVie Inc. market value which is $98. Current Last Sale of ACIU is $12.09 below from AbbVie Inc. current last sale which is $60.89.
AC Immune SA, a scientific level Swiss-based biopharmaceutical corporation, specializes in neurodegenerative sicknesses with three product applicants in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products meant to save you and modify sicknesses resulting from misfolding proteins. The company technology systems create antibodies, small molecules, and vaccines to deal with a vast spectrum of neurodegenerative symptoms. It offers its healing procedures to address Alzheimer disease and neurodegenerative diseases, including Parkinson, Down syndrome, and glaucoma. AC Immune SA turned into founded in 2003 and is primarily based in Lausanne, Switzerland.